Press releases
Apr 04, 2019
RhoVac submits application for the start of clinical phase IIb study with the drug candidate RV001
Regulatory press release: RhoVac AB (RhoVac) announced today, 4th April 2019, that the company has submitted the application for clinical trial (CTA,...[Read more]
Apr 02, 2019
RhoVac announces that all patients completed the follow-up phase of the clinical phase I / II study
RhoVac AB (RhoVac) announced today, 2nd April 2019, that all prostate cancer patients who participated in the clinical phase...[Read more]
Mar 20, 2019
FDA confirms RhoVac's application for a pre-IND meeting
RhoVac AB (publ) (RhoVac) hereby announces that FDA (US Food and Drug Administration) has accepted RhoVacs application for a...[Read more]
Announcements
17 January, 2019
RhoVac reports positive interim immune-results in the follow-up phase of company’s phase I/II clinical study
17 December, 2018
RhoVac announces that the first patient completed the follow-up phase of the clinical phase I / II study
14 November, 2018
RhoVac participates in international business conferences in the UK and the United States
Press Releases and Company Announcements published before 1 May 2017 in Swedish only.
RhoVac in Brief
RhoVac undertakes research and development of therapeutic cancer vaccines. The primary candidate, RV001, targets RhoC which is overexpressed in cancer cells with metastatic potential.
Because most cancers form metastases, RV001 can potentially be used to treat a broad range of cancers. RhoVac's concept focuses on eliminating metastatic cancer cells that may escape treatment of the parent tumour via other methods. Because RhoC is not expressed in the parent tumour, the company goal is to use the developed product in combination with another therapy -- specifically, treatment of the parent tumour by e.g. surgery, radiotherapy or chemotherapy together with treatment with the therapeutic cancer vaccine to combat metastasis.
